Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 01, 2026
Aptiv (APTV) Drops -20.7% Over 30 Days After Guidance Reduction

Aptiv (APTV) Drops -20.7% Over 30 Days After Guidance Reduction

Key Takeaways

  • Aptiv (APTV) declined roughly 20.7% over the last 30 days, from a closing price of about $56.47 on July 31 to $44.77 by late August.
  • The selloff accelerated after second-quarter 2026 results, when a reduction in full-year guidance overshadowed a modest earnings beat.
  • Management lowered 2026 revenue and earnings guidance, citing softer China production, reduced European OEM export schedules, program launch delays, and software revenue timing.
  • Several analysts trimmed ratings and price targets, and consensus earnings estimates were revised down roughly 10% over a 60-day period.
  • Longer-term diversification efforts, including double-digit non-automotive growth and share repurchases, remain intact but have not offset near-term execution concerns.

Aptiv’s Business Overview and Market Position

Aptiv PLC supplies advanced hardware and software solutions for the automotive sector along with adjacent markets. Its offerings include sensors, advanced compute platforms, high-voltage interconnect systems, and a software stack focused on vehicle electrification, active safety, and software-defined architectures. After the April 1, 2026 spin-off of its Electrical Distribution Systems business into Versigent, the company now operates through two main segments: Intelligent Systems and Engineered Components. I keep an eye on the stock because of its exposure to rising content per vehicle, ADAS adoption, electrification trends, and growth in robotics, aerospace, defense, and industrial applications.

APTV Stock Performance Over the Past 30 Days and Quarter

Shares of APTV fell about 20.7% in the last 30 days, sliding from a July 31 close of $56.47 to $44.77 by late August. The drop intensified around a single catalyst, with the stock falling more than 15% on August 4 after the company released its second-quarter results and trimmed its full-year outlook. Looking back further, the quarterly picture shows a steeper decline from near $73 in early June to the mid-$40s by the end of August, representing roughly a 38% drop over three months. This appears to reflect a sustained repricing rather than an isolated event.

Factors Behind the Recent 30-Day Move

The main driver was the August 4 earnings release. Aptiv posted adjusted earnings per share of $1.63, beating consensus estimates of around $1.42, while revenue reached approximately $3.27 billion, up about 2% year over year. Non-automotive revenue rose 12%. Those results were overshadowed by a cut to full-year 2026 guidance, with revenue now expected between $12.6 billion and $12.8 billion versus the prior $12.8 billion to $13.2 billion range, and adjusted EPS lowered to $5.60 to $5.80 from $5.70 to $6.10. Management pointed to roughly $300 million in midpoint reductions tied to China production changes, program launch delays, and software revenue timing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Reduced export schedules from luxury European OEMs and a softer free-cash-flow profile added pressure, leading several analysts to lower ratings and price targets along with a roughly 10% cut to current-year earnings estimates.

Quarterly Context and Broader Market Pressures

The three-month decline aligns with weakening automotive demand and execution uncertainty. China’s softer production environment and rising local competition have affected suppliers across the sector. The Versigent spin-off introduced stranded costs and transitional issues, while cash conversion faced headwinds from elevated inventories and separation expenses. Although new business awards and non-automotive revenue continued to advance, the market has focused on the gap between a solid long-term technology pipeline and uneven near-term revenue and free-cash-flow conversion. Repeated downward revisions to estimates reinforced the downward pressure on the shares.

What to Watch for APTV Going Forward

Investors will likely track China vehicle production trends and European OEM export schedules, which played a central role in the guidance cut. The pace of new program launches and conversion of the bookings pipeline into revenue will serve as key execution indicators. Progress in non-automotive areas such as robotics, aerospace, defense, and energy storage could support the diversification narrative, while software growth may influence margins. Free-cash-flow trends and the ongoing share-repurchase program will signal capital discipline. Additional analyst estimate changes, macroeconomic conditions, and any updates to full-year guidance in upcoming reports should help shape sentiment.

Using AI Tools for Market Analysis

In my own research process, I’ve found Tickeron’s AI Trading Bots helpful for exploring automated strategies across thousands of tickers. The platform offers a wide range of bots with varying approaches, holding periods, and performance metrics, making it straightforward to review options that align with specific objectives without needing to evaluate every available strategy.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: APTV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


APTV's Indicator enters downward trend

The Aroon Indicator for APTV entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 227 similar instances where the Aroon Indicator formed such a pattern. In 176 of the 227 cases the stock moved lower. This puts the odds of a downward move at 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APTV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where APTV's RSI Indicator exited the oversold zone, 23 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 67 cases where APTV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.

The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on APTV as a result. In 56 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

The Moving Average Convergence Divergence (MACD) for APTV just turned positive on September 01, 2026. Looking at past instances where APTV's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.

Following a +3.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where APTV advanced for three days, in 173 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.035) is normal, around the industry mean (6.969). P/E Ratio (19.747) is within average values for comparable stocks, (71.549). Projected Growth (PEG Ratio) (1.020) is also within normal values, averaging (1.471). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.454) is also within normal values, averaging (49.084).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. APTV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APTV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

Notable companies

The most notable companies in this group are AutoZone (NYSE:AZO), Advance Auto Parts (NYSE:AAP), Goodyear Tire & Rubber Company (The) (NASDAQ:GT).

Industry description

OEM or Original Equipment Manufacturer of auto parts refers to the original producer of a vehicles components, and so OEM car parts are usually identical to the parts used in producing the vehicle in the first place. OEM parts tend to fit the specifications of a particular model, and their compatibility is often guaranteed by the automaker itself. OEM parts could be more expensive to buy (compared to other vendors’ products) when a consumer goes for replacement. However, increased competition from aftermarket parts/third-party vendors could, in some cases, keep EOM prices in check. The industry might progress further in adopting newer technologies like 3D printing to boost supply chain performance and quality. Aptiv PLC, Magna International Inc. and BorgWarner Inc. are major OEMs for autos.

Market Cap

The average market capitalization across the Auto Parts: OEM Industry is 4.89B. The market cap for tickers in the group ranges from 1.93K to 69.98B. ORLY holds the highest valuation in this group at 69.98B. The lowest valued company is CREVF at 1.93K.

High and low price notable news

The average weekly price growth across all stocks in the Auto Parts: OEM Industry was 1%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -8%. SES experienced the highest price growth at 57%, while ECX experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Auto Parts: OEM Industry was -10%. For the same stocks of the Industry, the average monthly volume growth was 63% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 59
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 88
Seasonality Score: 29 (-100 ... +100)
View a ticker or compare two or three
APTV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of connected technologies and electrical systems for motor vehicles

Industry AutoPartsOEM

Industry
Auto Parts OEM
Address
Spitalstrasse 5
Phone
+41 525809600
Employees
140000
Web
https://www.aptiv.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
Aptiv (APTV) Drops -20.7% Over 30 Days After Guidance Reduction